Barriers and Attitudes of Primary Healthcare Physicians to Insulin Initiation and Intensification in Saudi Arabia
- PMID: 36554673
- PMCID: PMC9779059
- DOI: 10.3390/ijerph192416794
Barriers and Attitudes of Primary Healthcare Physicians to Insulin Initiation and Intensification in Saudi Arabia
Abstract
Saudi Arabia is a country with high prevalence of diabetes, uncontrolled diabetes, and diabetes-related complications. Poor glycemic control is multifactorial and could be explained in part by physician and patient reluctance toward insulin or insulin inertia. This study aimed to address physician barriers toward insulin therapy in primary care settings. It included 288 physicians from 168 primary healthcare centers (PHC) in the Jazan region of Saudi Arabia. Participants responded to questionnaire investigating physicians' attitude and barriers to insulin initiation and intensification in PHCs. In physician opinion, the most common barriers among their patients were fear of injection, lack of patient education, fear of hypoglycemia, and difficult administration. Physicians were reluctant to initiate insulin for T2D patients mostly due to patient non-adherence to blood sugar measurement, non-adherence to appointment or treatment, elderly patients, or due to patient refusal. Physicians' fear of hypoglycemia, lack of staff for patient education, and lack of updated knowledge were the primary clinician-related barriers. Exaggerated fears of insulin side effects, patient non-adherence, limited staff for patient's education, patient refusal, and inadequate consultation time were the main barriers to insulin acceptance and prescription.
Keywords: barriers; clinical inertia; insulin initiation; primary healthcare physicians; therapeutic inertia; type 2 diabetes.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Physicians' Practices in Diabetic Nephropathy in Primary Healthcare Centers in Jazan City, Saudi Arabia, 2023.Medicina (Kaunas). 2024 Feb 22;60(3):372. doi: 10.3390/medicina60030372. Medicina (Kaunas). 2024. PMID: 38541098 Free PMC article.
-
Insulin therapy attitudes and beliefs of physicians in Middle Eastern Arab countries.Fam Pract. 2013 Oct;30(5):560-7. doi: 10.1093/fampra/cmt022. Epub 2013 Jun 1. Fam Pract. 2013. PMID: 23729488
-
Prevalence of unwillingness to use insulin therapy and its associated attitudes amongst patients with Type 2 diabetes in Saudi Arabia.Prim Care Diabetes. 2016 Dec;10(6):415-424. doi: 10.1016/j.pcd.2016.05.007. Epub 2016 Jun 11. Prim Care Diabetes. 2016. PMID: 27297805
-
Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus.Diabetes Metab. 2017 Dec;43(6):501-511. doi: 10.1016/j.diabet.2017.06.003. Epub 2017 Jul 25. Diabetes Metab. 2017. PMID: 28754263 Review.
-
Pharmacological treatment of type 2 diabetes in Saudi Arabia: A consensus statement from the Saudi Society of Endocrinology and Metabolism (SSEM).Diabetes Metab Syndr. 2021 May-Jun;15(3):891-899. doi: 10.1016/j.dsx.2021.04.003. Epub 2021 Apr 20. Diabetes Metab Syndr. 2021. PMID: 33895710 Review.
Cited by
-
Factors associated with psychological insulin resistance among patients with type 2 diabetes in China.Front Endocrinol (Lausanne). 2024 Jul 5;15:1368132. doi: 10.3389/fendo.2024.1368132. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39036047 Free PMC article.
-
A Hybrid Model of In-Person and Telemedicine Diabetes Education and Care for Management of Patients with Uncontrolled Type 2 Diabetes Mellitus: Findings and Implications from a Multicenter Prospective Study.Telemed Rep. 2024 Feb 19;5(1):46-57. doi: 10.1089/tmr.2024.0003. eCollection 2024. Telemed Rep. 2024. PMID: 38469168 Free PMC article.
-
Trends in diabetes prevalence, awareness, treatment, and control in French-speaking Switzerland.Sci Rep. 2024 Feb 28;14(1):4839. doi: 10.1038/s41598-024-54856-6. Sci Rep. 2024. PMID: 38418618 Free PMC article.
-
Real-World Effectiveness of My Dose Coach™-Assisted Basal Insulin Titration in People with Type 2 Diabetes in Saudi Arabia and Kuwait.Diabetes Ther. 2025 Jul 21. doi: 10.1007/s13300-025-01772-1. Online ahead of print. Diabetes Ther. 2025. PMID: 40690110
-
Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi Arabia.Adv Ther. 2024 Nov;41(11):4140-4152. doi: 10.1007/s12325-024-02978-8. Epub 2024 Sep 11. Adv Ther. 2024. PMID: 39261418 Free PMC article.
References
-
- International Diabetes Federation . IDF Diabetes Atlas. 10th ed. International Diabetes Federation; Brussels, Belgium: 2021.
-
- Davies M.J., Aroda V.R., Collins B.S., Gabbay R.A., Green J., Maruthur N.M., Rosas S.E., Del Prato S., Mathieu C., Mingrone G., et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2022;45:2753–2786. doi: 10.2337/dci22-0034. - DOI - PMC - PubMed
-
- Gabbay R.A., Kendall D., Beebe C., Cuddeback J., Hobbs T., Khan N.D., Leal S., Miller E., Novak L.M., Rajpathak S.N., et al. Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. Clin. Diabetes. 2020;38:371–381. doi: 10.2337/cd20-0053. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical